- Home
- SHMD vs EDIT Comparison
SHMD vs EDIT Comparison
Compare SHMD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | EDIT |
|---|---|---|
| Founded | 1864 | 2013 |
| Country | Germany | United States |
| Employees | 676 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.4M | 310.9M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SHMD | EDIT |
|---|---|---|
| Price | $7.46 | $2.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.30 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $2.00 | $1.47 |
| 52 Week High | $10.65 | $4.54 |
Technical Indicators
Market Signals| Indicator | SHMD | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 64.55 | 37.00 |
| Support Level | $5.07 | $2.42 |
| Resistance Level | $9.34 | $2.76 |
| Average True Range (ATR) | 0.58 | 0.21 |
| MACD | 0.17 | -0.08 |
| Stochastic Oscillator | 89.52 | 7.74 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.